Vikram Purohit
Stock Analyst at Morgan Stanley
(0.71)
# 3,892
Out of 4,944 analysts
154
Total ratings
25.86%
Success rate
-15.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics | Upgrades: Overweight | $62 → $75 | $64.04 | +17.11% | 8 | Aug 6, 2025 | |
| ABSI Absci | Maintains: Overweight | $7 → $6.4 | $2.97 | +115.49% | 2 | Jul 28, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $5.41 | -7.58% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $196.02 | +27.54% | 19 | May 5, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $81.61 | -20.35% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $105.23 | +80.56% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $15.90 | +120.13% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.87 | +84.80% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $21.87 | +41.75% | 2 | Sep 11, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $71.91 | -77.75% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $4.22 | +610.90% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $14.74 | -32.16% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $2.63 | +128.14% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $8.10 | +418.52% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $39.87 | +2.83% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $26.83 | +49.09% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.24 | +480.36% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $18.85 | +101.59% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $10.75 | +86.05% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $11.92 | -16.11% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.67 | +1,217.37% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $9.81 | +103.87% | 2 | Aug 5, 2020 |
Halozyme Therapeutics
Aug 6, 2025
Upgrades: Overweight
Price Target: $62 → $75
Current: $64.04
Upside: +17.11%
Absci
Jul 28, 2025
Maintains: Overweight
Price Target: $7 → $6.4
Current: $2.97
Upside: +115.49%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $5.41
Upside: -7.58%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $196.02
Upside: +27.54%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $81.61
Upside: -20.35%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $105.23
Upside: +80.56%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $15.90
Upside: +120.13%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.87
Upside: +84.80%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $21.87
Upside: +41.75%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $71.91
Upside: -77.75%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $4.22
Upside: +610.90%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $14.74
Upside: -32.16%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $2.63
Upside: +128.14%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $8.10
Upside: +418.52%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $39.87
Upside: +2.83%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $26.83
Upside: +49.09%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.24
Upside: +480.36%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $18.85
Upside: +101.59%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $10.75
Upside: +86.05%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $11.92
Upside: -16.11%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.67
Upside: +1,217.37%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $9.81
Upside: +103.87%